173 related articles for article (PubMed ID: 22136063)
1. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.
Henkin J; Volpert OV
Expert Opin Ther Targets; 2011 Dec; 15(12):1369-86. PubMed ID: 22136063
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.
Huang H; Campbell SC; Bedford DF; Nelius T; Veliceasa D; Shroff EH; Henkin J; Schneider A; Bouck N; Volpert OV
Mol Cancer Res; 2004 Oct; 2(10):541-50. PubMed ID: 15498928
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
4. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.
Quesada AJ; Nelius T; Yap R; Zaichuk TA; Alfranca A; Filleur S; Volpert OV; Redondo JM
Cell Death Differ; 2005 Jun; 12(6):649-58. PubMed ID: 15818399
[TBL] [Abstract][Full Text] [Related]
5. Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.
Chan LY; Craik DJ; Daly NL
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26464514
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment.
Rico MC; Castaneda JL; Manns JM; Uknis AB; Sainz IM; Safadi FF; Popoff SN; Dela Cadena RA
J Cell Physiol; 2007 May; 211(2):504-12. PubMed ID: 17219411
[TBL] [Abstract][Full Text] [Related]
7. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
8. BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors.
Tsuchida R; Osawa T; Wang F; Nishii R; Das B; Tsuchida S; Muramatsu M; Takahashi T; Inoue T; Wada Y; Minami T; Yuasa Y; Shibuya M
Oncogene; 2014 Jul; 33(29):3803-11. PubMed ID: 24013228
[TBL] [Abstract][Full Text] [Related]
9. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
10. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.
Veliceasa D; Ivanovic M; Hoepfner FT; Thumbikat P; Volpert OV; Smith ND
FEBS J; 2007 Dec; 274(24):6365-77. PubMed ID: 18021253
[TBL] [Abstract][Full Text] [Related]
11. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.
Filleur S; Volpert OV; Degeorges A; Voland C; Reiher F; Clézardin P; Bouck N; Cabon F
Genes Dev; 2001 Jun; 15(11):1373-82. PubMed ID: 11390357
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.
Isenberg JS; Ridnour LA; Perruccio EM; Espey MG; Wink DA; Roberts DD
Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13141-6. PubMed ID: 16150726
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis.
Roberts DD; Isenberg JS; Ridnour LA; Wink DA
Clin Cancer Res; 2007 Feb; 13(3):795-8. PubMed ID: 17289869
[TBL] [Abstract][Full Text] [Related]
14. Beta 1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides.
Wilson KE; Li Z; Kara M; Gardner KL; Roberts DD
J Immunol; 1999 Oct; 163(7):3621-8. PubMed ID: 10490955
[TBL] [Abstract][Full Text] [Related]
15. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight.
Danese S
Pathobiology; 2008; 75(1):22-4. PubMed ID: 18334836
[TBL] [Abstract][Full Text] [Related]
16. [Neoplasms and angiogenesis].
Lewy-Trenda I
Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
[TBL] [Abstract][Full Text] [Related]
17. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
Li D; Finley SD
Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
[TBL] [Abstract][Full Text] [Related]
18. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of anti-angiogenic peptides: A structural link.
Dings RP; Nesmelova I; Griffioen AW; Mayo KH
Angiogenesis; 2003; 6(2):83-91. PubMed ID: 14739615
[TBL] [Abstract][Full Text] [Related]
20. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
